Table 3.
Overall enoxaparin dose interventions
| Variable | Patients | Variable | Patients |
|---|---|---|---|
| Dose adjustment after initial anti-Xa result (n=53) | 13 (24.5) | Dose adjustment after second anti-Xa result (n=3) | |
| Increased appropriately | 6 (11.3) | Increase, mg/kg | 1.64 (1.28 – 2.30) |
| Decreased appropriately | 4 (7.5) | Decrease, mg/kg | 0.72 |
| Dose adjusted inappropriately | 2 (3.8) | Anti-Xa level at third measurement (n=14) | |
| Dose adjustment indicated but not performed | 28 (52.8) | Therapeutic | 5 (35.7) |
| No dose adjustment indicated | 12 (22.6) | Subtherapeutic | 2 (14.3) |
| Enoxaparin discontinued prior to dose adjustment | 1 (1.9) | Supratherapeutic | 1 (7.1) |
| Dose adjustment after initial anti-Xa result (n=10) | Third anti-Xa level not measured | 6 (42.9) | |
| Increase, mg/kg | 1.31 (1.01 – 2.09) | Dose adjustment after third anti-Xa result (n=3) | |
| Decrease, mg/kg | 0.87 (0.76 – 0.88) | Enoxaparin discontinued | 2 (66.7) |
| Anti-Xa level at second measurement (n=39) | Dose adjustment indicated but not performed | 1 (33.3) | |
| Therapeutic | 2 (5.1) | Total cumulative received enoxaparin, mg | 460 (290 – 720) |
| Subtherapeutic | 12 (30.8) | ||
| Supratherapeutic | 2 (5.1) | ||
| Second anti-Xa level not measured | 23 (59.0) | ||
| Dose adjustment after second anti-Xa result (n=16) | |||
| Increased appropriately | 2 (12.5) | ||
| Decreased appropriately | 1 (6.2) | ||
| Dose adjusted inappropriately | 2 (12.5) | ||
| Dose adjustment indicated but not performed | 6 (37.5) | ||
| No dose adjustment indicated | 2 (12.5) | ||
| Enoxaparin discontinued prior to dose adjustment | 3 (18.8) |
Data are presented as number (percentage) or median (interquartile range)